Logo image of 1EXEL.MI

EXELIXIS INC (1EXEL.MI) Stock Fundamental Analysis

Europe - BIT:1EXEL - US30161Q1040 - Common Stock

33.18 EUR
+0.3 (+0.91%)
Last: 9/12/2025, 7:00:00 PM
Fundamental Rating

8

Taking everything into account, 1EXEL scores 8 out of 10 in our fundamental rating. 1EXEL was compared to 75 industry peers in the Biotechnology industry. 1EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. 1EXEL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes 1EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

1EXEL had positive earnings in the past year.
In the past year 1EXEL had a positive cash flow from operations.
Each year in the past 5 years 1EXEL has been profitable.
In the past 5 years 1EXEL always reported a positive cash flow from operatings.
1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCF1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

1EXEL's Return On Assets of 22.49% is amongst the best of the industry. 1EXEL outperforms 92.00% of its industry peers.
The Return On Equity of 1EXEL (29.62%) is better than 92.00% of its industry peers.
1EXEL's Return On Invested Capital of 25.22% is amongst the best of the industry. 1EXEL outperforms 96.00% of its industry peers.
1EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is below the industry average of 13.78%.
The last Return On Invested Capital (25.22%) for 1EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1EXEL.MI Yearly ROA, ROE, ROIC1EXEL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

1EXEL has a Profit Margin of 27.01%. This is amongst the best in the industry. 1EXEL outperforms 85.33% of its industry peers.
1EXEL's Profit Margin has declined in the last couple of years.
1EXEL has a better Operating Margin (33.71%) than 89.33% of its industry peers.
In the last couple of years the Operating Margin of 1EXEL has declined.
1EXEL has a Gross Margin of 96.59%. This is amongst the best in the industry. 1EXEL outperforms 92.00% of its industry peers.
1EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
1EXEL.MI Yearly Profit, Operating, Gross Margins1EXEL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

1EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 1EXEL has less shares outstanding
1EXEL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for 1EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1EXEL.MI Yearly Shares Outstanding1EXEL.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
1EXEL.MI Yearly Total Debt VS Total Assets1EXEL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 11.85 indicates that 1EXEL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.85, 1EXEL belongs to the best of the industry, outperforming 89.33% of the companies in the same industry.
1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.85
ROIC/WACC2.64
WACC9.57%
1EXEL.MI Yearly LT Debt VS Equity VS FCF1EXEL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

1EXEL has a Current Ratio of 3.51. This indicates that 1EXEL is financially healthy and has no problem in meeting its short term obligations.
1EXEL has a Current ratio of 3.51. This is in the better half of the industry: 1EXEL outperforms 66.67% of its industry peers.
A Quick Ratio of 3.44 indicates that 1EXEL has no problem at all paying its short term obligations.
1EXEL has a better Quick ratio (3.44) than 65.33% of its industry peers.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
1EXEL.MI Yearly Current Assets VS Current Liabilites1EXEL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.74% over the past year.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
1EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.73%.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

Based on estimates for the next years, 1EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 22.20% on average per year.
1EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.31% yearly.
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue Next Year7.29%
Revenue Next 2Y10.13%
Revenue Next 3Y11.67%
Revenue Next 5Y10.31%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1EXEL.MI Yearly Revenue VS Estimates1EXEL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
1EXEL.MI Yearly EPS VS Estimates1EXEL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 18.85, 1EXEL is valued on the expensive side.
85.33% of the companies in the same industry are more expensive than 1EXEL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.41, 1EXEL is valued a bit cheaper.
A Price/Forward Earnings ratio of 13.50 indicates a correct valuation of 1EXEL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1EXEL indicates a rather cheap valuation: 1EXEL is cheaper than 86.67% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, 1EXEL is valued a bit cheaper.
Industry RankSector Rank
PE 18.85
Fwd PE 13.5
1EXEL.MI Price Earnings VS Forward Price Earnings1EXEL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

82.67% of the companies in the same industry are more expensive than 1EXEL, based on the Enterprise Value to EBITDA ratio.
1EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 86.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14
EV/EBITDA 11.69
1EXEL.MI Per share data1EXEL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1EXEL's earnings are expected to grow with 26.04% in the coming years.
PEG (NY)0.68
PEG (5Y)1.49
EPS Next 2Y25.29%
EPS Next 3Y26.04%

More info and screens

0

5. Dividend

5.1 Amount

1EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

BIT:1EXEL (9/12/2025, 7:00:00 PM)

33.18

+0.3 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners95.32%
Inst Owner ChangeN/A
Ins Owners2.23%
Ins Owner ChangeN/A
Market Cap8.93B
Analysts77.69
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)1.16%
EPS NQ rev (3m)N/A
EPS NY rev (1m)3.37%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 18.85
Fwd PE 13.5
P/S 4.73
P/FCF 14
P/OCF 13.67
P/B 5.19
P/tB 5.36
EV/EBITDA 11.69
EPS(TTM)1.76
EY5.3%
EPS(NY)2.46
Fwd EY7.41%
FCF(TTM)2.37
FCFY7.14%
OCF(TTM)2.43
OCFY7.31%
SpS7.01
BVpS6.39
TBVpS6.19
PEG (NY)0.68
PEG (5Y)1.49
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.85
F-Score8
WACC9.57%
ROIC/WACC2.64
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.29%
Revenue Next 2Y10.13%
Revenue Next 3Y11.67%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year42.25%
EBIT Next 3Y34.74%
EBIT Next 5YN/A
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%